Carregando...

The Efficacy of the Novel Dual PI3-Kinase/mTOR Inhibitor NVP-BEZ235 Compared to Rapamycin in Renal Cell Carcinoma

PURPOSE: Inhibitors of TORC1 have been shown to be active in patients with metastatic renal cell carcinoma (RCC). As the PI3-K pathway activates numerous other kinases, transcription factors and proteins associated with cell growth and survival besides mTOR, disruption of this pathway upstream of mT...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Principais autores: Cho, Daniel C., Cohen, Matthew B., Panka, David J., Collins, Michael, Ghebremichael, Musie, Atkins, Michael B., Signoretti, Sabina, Mier, James W.
Formato: Artigo
Idioma:Inglês
Publicado em: 2010
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2905505/
https://ncbi.nlm.nih.gov/pubmed/20606035
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-09-3022
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!